CL2013000308A1 - Uso de compuestos heterociclicos con nitrogeno, oxigeno o azufre, para tratar una imperfeccion de la piel tal como una herida superficial, cicatriz o arruga; composiciones farmaceuticas. - Google Patents

Uso de compuestos heterociclicos con nitrogeno, oxigeno o azufre, para tratar una imperfeccion de la piel tal como una herida superficial, cicatriz o arruga; composiciones farmaceuticas.

Info

Publication number
CL2013000308A1
CL2013000308A1 CL2013000308A CL2013000308A CL2013000308A1 CL 2013000308 A1 CL2013000308 A1 CL 2013000308A1 CL 2013000308 A CL2013000308 A CL 2013000308A CL 2013000308 A CL2013000308 A CL 2013000308A CL 2013000308 A1 CL2013000308 A1 CL 2013000308A1
Authority
CL
Chile
Prior art keywords
scar
wrinkle
sulfur
treat
nitrogen
Prior art date
Application number
CL2013000308A
Other languages
English (en)
Spanish (es)
Inventor
Guang L Jiang
Robert M Burk
Wha Bin Im
Frederick C Beddingfield
Scott M Whitcup
Larry A Wheeler
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2013000308A1 publication Critical patent/CL2013000308A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
CL2013000308A 2010-07-30 2013-01-30 Uso de compuestos heterociclicos con nitrogeno, oxigeno o azufre, para tratar una imperfeccion de la piel tal como una herida superficial, cicatriz o arruga; composiciones farmaceuticas. CL2013000308A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36923210P 2010-07-30 2010-07-30
US41911510P 2010-12-02 2010-12-02

Publications (1)

Publication Number Publication Date
CL2013000308A1 true CL2013000308A1 (es) 2013-04-12

Family

ID=44543791

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000308A CL2013000308A1 (es) 2010-07-30 2013-01-30 Uso de compuestos heterociclicos con nitrogeno, oxigeno o azufre, para tratar una imperfeccion de la piel tal como una herida superficial, cicatriz o arruga; composiciones farmaceuticas.

Country Status (18)

Country Link
US (1) US20120136011A1 (enExample)
EP (1) EP2598140B1 (enExample)
JP (1) JP2013536183A (enExample)
KR (1) KR20130130694A (enExample)
CN (1) CN103068382A (enExample)
AR (1) AR082428A1 (enExample)
AU (1) AU2011282549A1 (enExample)
BR (1) BR112013002319A2 (enExample)
CA (1) CA2806982A1 (enExample)
CL (1) CL2013000308A1 (enExample)
CO (1) CO6680670A2 (enExample)
MX (1) MX2013001227A (enExample)
NZ (1) NZ607306A (enExample)
PH (1) PH12013500205A1 (enExample)
RU (1) RU2013108394A (enExample)
SG (1) SG187653A1 (enExample)
TW (1) TW201210601A (enExample)
WO (1) WO2012016109A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697458B2 (en) 2009-04-22 2014-04-15 Shat-R-Shield, Inc. Silicone coated light-emitting diode
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) * 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) * 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8741281B2 (en) * 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) * 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) * 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) * 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
EP2605762A1 (en) * 2010-08-19 2013-06-26 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US8926963B2 (en) * 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
CA2891595A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
WO2014078446A2 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
CA2924843A1 (en) * 2013-09-27 2015-04-02 Allergan, Inc. Compounds and methods for skin repair
RU2625548C1 (ru) * 2015-04-29 2017-07-14 Жанна Юрьевна Юсова Способ коррекции возрастных изменений кожи лица
TWI593403B (zh) 2016-12-01 2017-08-01 徐藝庭 遺體臉部毀損之修復方法
RU2663391C1 (ru) * 2018-01-30 2018-08-03 Игорь Николаевич Бондаренко Способ эстетической коррекции мягких тканей лица

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (en) * 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
JP4618548B2 (ja) * 1999-11-24 2011-01-26 小野薬品工業株式会社 骨量低下疾患治療剤
JP4273407B2 (ja) * 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
HUE029417T2 (en) * 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
JP5319065B2 (ja) * 2003-02-11 2013-10-16 アラーガン インコーポレイテッド 眼圧降下剤としての１０，１０−ジアルキルプロスタン酸誘導体
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
EP1782829A1 (en) * 2004-08-10 2007-05-09 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for hyperkalemia containing ep4 agonist
JP2006321737A (ja) * 2005-05-18 2006-11-30 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを含有する神経変性疾患の予防、治療および／または進展抑制剤
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
JP5069752B2 (ja) * 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
JP2010513551A (ja) * 2006-12-18 2010-04-30 アラーガン インコーポレイテッド 胃腸疾患の治療方法および組成物
CN101686985A (zh) * 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical

Also Published As

Publication number Publication date
CN103068382A (zh) 2013-04-24
TW201210601A (en) 2012-03-16
CO6680670A2 (es) 2013-05-31
BR112013002319A2 (pt) 2016-05-24
AU2011282549A1 (en) 2013-02-28
EP2598140B1 (en) 2015-01-14
NZ607306A (en) 2015-03-27
MX2013001227A (es) 2013-04-24
WO2012016109A3 (en) 2012-03-22
US20120136011A1 (en) 2012-05-31
PH12013500205A1 (en) 2017-08-23
JP2013536183A (ja) 2013-09-19
AR082428A1 (es) 2012-12-05
SG187653A1 (en) 2013-03-28
KR20130130694A (ko) 2013-12-02
EP2598140A2 (en) 2013-06-05
RU2013108394A (ru) 2014-09-10
WO2012016109A2 (en) 2012-02-02
CA2806982A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
CY1114766T1 (el) Χρηση μπεθανεχολης για αντιμετωπιση ξηροστομιας
ECSP14027269A (es) Picolinamidas macrocíclicas como fungicidas
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CL2012003385A1 (es) Tratamiento para la incontinencia.
NI201000103A (es) Formas cristalinas de dimetoxi docetaxel y metodo para preparar el mismo.
BR112013013914A2 (pt) derivados de hidantoína úteis como inibidores de kv3
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
ECSP13012420A (es) Derivados de tetrahidro-pirido-pirimidina
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CL2013001579A1 (es) Uso de una composicion farmaceutica que comprende un compuesto agonista ep4 para tratar marcas de la piel tales como heridas superficiales, cicatrices o arrugas.
BR112015012907A2 (pt) composição de cuidado pessoal
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
MX2013005995A (es) Composicion topica que promueve la melanina.
CL2011002041A1 (es) Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes.
CY1117163T1 (el) Ιμιδαζοπυριδαζινες ως αναστολεις κινασης ακτ
PH12015502405A1 (en) Methods and compositions for wound healing
GT201400090A (es) 2-tiopirimidinonas
CL2014000172A1 (es) Composicion en spray que comprende a) un portador de oxigeno, tal como hemoglobina o mioglobina; y b) al menos un ingrediente adicional; metodo para preparar la composicion; proceso para purificar un portador de oxigeno; y su uso para el tratamiento externo de heridas.
PH12013500205A1 (en) Compounds and methods for skin repair
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
GT201200345A (es) Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica
BR112013014388A2 (pt) suspensão aquosa de um inibidor de encefalinase e processo de preparação de uma suspensão aquosa
BR112012017393A2 (pt) derivados de 2,5,7-oxazolpirimidina substituída
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina